New Vaccine Design and Delivery Technologies
Open accessAbstract
Technological advances in immunology, protein design, and genetic delivery have unlocked new possibilities for vaccine concepts and delivery technologies that were previously inaccessible. These next-generation vaccine design efforts are particularly promising in their potential to provide solutions to challenging targets for which conventional approaches have proven ineffective-for example, a universal influenza vaccine. In this perspective, we discuss emerging approaches to vaccine design and engineering based on recent insights into immunology, structural biology, computational biology, and immunoengineering. We anticipate that these cutting-edge, interdisciplinary approaches will lead to breakthrough vaccine concepts for ever-evolving and (re)emerging influenza viruses, with important ramifications for global public health.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Improved antigen delivery methods such as liposomes, polymeric particles, inorganic particles, outer membrane vesicles, immunostimulating complexes, and self-assembling protein nanoparticles have the potential to optimally enhance and skew immune responses to pathogens against which traditional vaccine approaches have been unsuccessful.
“These, and other methods such as self-assembling protein nanoparticles, have the potential to optimally enhance and skew the immune response to pathogens against which traditional vaccine approaches have proven to be unsuccessful129,134.”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Krammer, F., Smith, G. J. D., Fouchier, R. A. M., Peiris, M. J. S., Kedzierska, K., Doherty, P. C., Palese, P., Shaw, M. L., Treanor, J. J., Webster, R. G., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0002-y · Cited by 1,591 · see citing works
The coming of age of de novo protein design
Huang, P.-S., Boyken, S. E., & Baker, D. (2016) · Nature · doi:10.1038/nature19946 · Cited by 1,478 · see citing works
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126 · see citing works
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073 · see citing works
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
Kanekiyo, M., Wei, C., Yassine, H. M., McTamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W., Wang, L., & Nabel, G. J. (2013) · Nature · doi:10.1038/nature12202 · Cited by 887 · see citing works
Self-citationStructure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883 · see citing works
Type I interferon: friend or foe?
Trinchieri, G. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20101664 · Cited by 838 · see citing works
Virus attenuation by genome-scale changes in codon pair bias
Coleman, J. R., Papamichail, D., Skiena, S., Futcher, B., Wimmer, E., & Mueller, S. (2008) · Science · doi:10.1126/science.1155761 · Cited by 715 · see citing works
Harrison, S. C. (2015) · Virology · doi:10.1016/j.virol.2015.03.043 · Cited by 705 · see citing works
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C., Kanekiyo, M., Kong, W., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 702 · see citing works
Self-citationAntibodies, viruses and vaccines
Burton, D. R. (2002) · Nature Reviews Immunology · doi:10.1038/nri891 · Cited by 637 · see citing works
A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen
Impagliazzo, A., Milder, F. J., Kuipers, H., Wagner, M. V., Zhu, X., Hoffman, R. M. B., van Meersbergen, R., Huizingh, J., Wanningen, P., Verspuij, J. W. A., et al. (2015) · Science · doi:10.1126/science.aac7263 · Cited by 591 · see citing works
HIV-1 neutralizing antibodies induced by native-like envelope trimers
Sanders, R. W., van Gils, M. J., Derking, R., Sok, D., Ketas, T. J., Burger, J. A., Ozorowski, G., Cupo, A., Simonich, C. A. L., Goo, L., et al. (2015) · Science · doi:10.1126/science.aac4223 · Cited by 499 · see citing works
Structure of the Uncleaved Human H1 Hemagglutinin from the Extinct 1918 Influenza Virus
Stevens, J., Corper, A. L., Basler, C. F., Taubenberger, J. K., Palese, P., & Wilson, I. A. (2004) · Science · doi:10.1126/science.1093373 · Cited by 477 · see citing works
Sanders, R. W., Vesanen, M., Schülke, N., Master, A., Schiffner, L., Kalyanaraman, R., Paluch, M. T., Berkhout, B., Maddon, P. J., Olson, W. C., et al. (2002) · Journal of Virology · doi:10.1128/jvi.76.17.8875-8889.2002 · Cited by 441 · see citing works
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design
Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O., & Gregorio, E. D. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151960 · Cited by 438 · see citing works
Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera
Ngwuta, J. O., Chen, M., Modjarrad, K., Joyce, M. G., Kanekiyo, M., Kumar, A., Yassine, H. M., Moin, S. M., Killikelly, A. M., Chuang, G., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4241 · Cited by 433 · see citing works
Self-citationBurton, D. R., Poignard, P., Stanfield, R. L., & Wilson, I. A. (2012) · Science · doi:10.1126/science.1225416 · Cited by 416 · see citing works
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
Krarup, A., Truan, D., Furmanova-Hollenstein, P., Bogaert, L., Bouchier, P., Bisschop, I. J. M., Widjojoatmodjo, M. N., Zahn, R., Schuitemaker, H., McLellan, J. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9143 · Cited by 383 · see citing works
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
Kanekiyo, M., Bu, W., Joyce, M. G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.043 · Cited by 367 · see citing works
Self-citationInfluenza A and B viruses expressing altered NS1 proteins: A vaccine approach
Talon, J., Salvatore, M., O’Neill, R. E., Nakaya, Y., Zheng, H., Muster, T., García‐Sastre, A., & Palese, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070525997 · Cited by 320 · see citing works
McGuire, A. T., Hoot, S., Dreyer, A. M., Lippy, A., Stuart, A., Cohen, K. W., Jardine, J., Menis, S., Scheid, J. F., West, A. P., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122824 · Cited by 309 · see citing works
Live attenuated influenza virus vaccines by computer-aided rational design
Mueller, S., Coleman, J. R., Papamichail, D., Ward, C. B., Nimnual, A., Futcher, B., Skiena, S., & Wimmer, E. (2010) · Nature Biotechnology · doi:10.1038/nbt.1636 · Cited by 275 · see citing works
Adaptation and Growth Characteristics of Influenza Virus at 25° C
MAASSAB, H. F. (1967) · Nature · doi:10.1038/213612a0 · Cited by 274 · see citing works
The HIV ‐1 envelope glycoprotein structure: nailing down a moving target
Ward, A. B., & Wilson, I. A. (2017) · Immunological Reviews · doi:10.1111/imr.12507 · Cited by 245 · see citing works
Native‐like Env trimers as a platform for HIV ‐1 vaccine design
Sanders, R. W., & Moore, J. P. (2017) · Immunological Reviews · doi:10.1111/imr.12481 · Cited by 227 · see citing works
Bommakanti, G., Citron, M. P., Hepler, R. W., Callahan, C., Heidecker, G. J., Najar, T. A., Lu, X., Joyce, J. G., Shiver, J. W., Casimiro, D. R., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007465107 · Cited by 214 · see citing works
Eggink, D., Goff, P. H., & Palese, P. (2013) · Journal of Virology · doi:10.1128/jvi.02608-13 · Cited by 187 · see citing works
McGuire, A. T., Gray, M. D., Dosenovic, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms10618 · Cited by 186 · see citing works
Tulloch, F., Atkinson, N. J., Evans, D. J., Ryan, M. D., & Simmonds, P. (2014) · eLife · doi:10.7554/elife.04531 · Cited by 178 · see citing works
Godley, L. A., Pfeifer, J. B., Steinhauer, D. A., Ely, B. K., Shaw, G., Kaufmann, R., Suchanek, E. G., Pabo, C. O., Skehel, J. J., Wiley, D. C., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90140-8 · Cited by 175 · see citing works
Generation of influenza A viruses as live but replication-incompetent virus vaccines
Si, L., Xu, H., Zhou, X., et al. (2016) · Science · doi:10.1126/science.aah5869 · Cited by 171 · see citing works
Barnes, D., Kunitomi, M., Vignuzzi, M., Saksela, K., & Andino, R. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.08.003 · Cited by 166 · see citing works
MicroRNA-mediated species-specific attenuation of influenza A virus
Perez, J. T., Pham, A. M., Lorini, M. H., Chua, M. A., Steel, J., & tenOever, B. R. (2009) · Nature Biotechnology · doi:10.1038/nbt.1542 · Cited by 146 · see citing works
Duan, H., Chen, X., Boyington, J. C., Cheng, C., Zhang, Y., Jafari, A. J., Stephens, T., Tsybovsky, Y., Kalyuzhniy, O., Zhao, P., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.005 · Cited by 139 · see citing works
What Are the Most Powerful Immunogen Design Vaccine Strategies?Preprint
Burton, D. R. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a030262 · Cited by 132 · see citing works
Chandramouli, S., Ciferri, C., Nikitin, P. A., Calò, S., Gerrein, R., Balabanis, K. A., Monroe, J. E., Hebner, C. M., Lilja, A. E., Settembre, E. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms9176 · Cited by 128 · see citing works
Cruciani, M., Mengoli, C., Serpelloni, G., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.10.040 · Cited by 102 · see citing works
Rutten, L., Lai, Y., Blokland, S., Truan, D., Bisschop, I. J. M., Strokappe, N. M., Koornneef, A., van Manen, D., Chuang, G., Farney, S. K., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.061 · Cited by 101 · see citing works
Advances in antiviral vaccine development
Graham, B. S. (2013) · Immunological Reviews · doi:10.1111/imr.12098 · Cited by 100 · see citing works
Attenuation of RNA viruses by redirecting their evolution in sequence space
Moratorio, G., Henningsson, R., Barbezange, C., Carrau, L., Bordería, A. V., Blanc, H., Beaucourt, S. M., Poirier, E. Z., Vallet, T., Boussier, J., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.88 · Cited by 91 · see citing works
A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin
Stech, J., Garn, H., Wegmann, M., Wagner, R., & Hd, K. (2005) · Nature Medicine · doi:10.1038/nm1256 · Cited by 89 · see citing works
Genome-wide identification of interferon-sensitive mutations enables influenza vaccine design
Du, Y., Li, X., Shi, Y., Zhang, T.-H., Wu, N. C., Dai, L., Gong, D., Brar, G., Shu, S., Luo, J., et al. (2018) · Science · doi:10.1126/science.aan8806 · Cited by 85 · see citing works
MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies
Langlois, R. A., Albrecht, R. A., Kimble, J. B., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2666 · Cited by 81 · see citing works
Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains
Joyce, M. G., Georgiev, I. S., Yang, Y., Druz, A., Geng, H., Chuang, G., Kwon, Y. D., Pancera, M., Rawi, R., Sastry, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.016 · Cited by 58 · see citing works
Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1
Mössler, C., Groiss, F., Wolzt, M., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.10.061 · Cited by 53 · see citing works
Design and Structure of an Engineered Disulfide-Stabilized Influenza Virus Hemagglutinin Trimer
Lee, P. S., Zhu, X., Yu, W., & Wilson, I. A. (2015) · Journal of Virology · doi:10.1128/jvi.00808-15 · Cited by 47 · see citing works
Song, L., Xiong, D., Kang, X., Yang, Y., Wang, J., Guo, Y., Xu, H., Chen, S., Peng, D., Pan, Z., et al. (2015) · BMC Biotechnology · doi:10.1186/s12896-015-0195-z · Cited by 46 · see citing works
Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity
Prchal, M., Pilz, A., Simma, O., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.016 · Cited by 44 · see citing works
Zhang, P., Gorman, J., Geng, H., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.002 · Cited by 41 · see citing works
What Are the Most Powerful Immunogen Design Vaccine Strategies?Preprint
Kwong, P. D. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a029470 · Cited by 30 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593 · see citing works
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532 · see citing works
Self-citation
- Authors
- Kanekiyo, M., Ellis, D., & King, N. P.
- Affiliations
- National Institutes of Health (US)
- University of Washington (US)
- Corresponding author
- Kanekiyo, Masaru
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-04-08
- Volume
- 219
- Issue
- Supplement_1
- Pages
- S88-S96
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC6452296
- OpenAlex
- W2912432120
- Cited by
- 69
- References
- 51
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 4 · 2023: 10 · 2022: 8 · 2021: 14 · 2020: 12 · 2019: 4
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Infectious Diseases (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- Open Philanthropy Project
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- vaccine design, universal influenza vaccine, influenza virus, immunoengineering, protein design, structural biology, computational biology
- MeSH terms
- Broadly Neutralizing Antibodies, Animals, Antibodies, Viral, Epitopes, Antigens, Viral, Disease Models, Animal, Humans, Influenza, Human, Influenza Vaccines, Orthomyxoviridae, Orthomyxoviridae Infections, RNA, Messenger, Vaccination, Protein Engineering, Antigen Presentation, Hemagglutinin Glycoproteins, Influenza Virus, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
